Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: an economic analysis
Health Quality Ontario
Record ID 32016000556
English
Authors' recommendations:
Compared with no testing, MRD testing by flow cytometry in newly diagnosed patients with precursor B-cell ALL represents good value for money at commonly used willingness-to-pay thresholds of $50,000/QALY and $100,000/
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/economic-analysis-mrd-1603-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Gene Rearrangement
- Neoplasm, Residual
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.